Business Wire

Reply S.p.A: The Board of Directors Approves the Half-year Financial Report as of 30 June 2020

31.7.2020 14:56:00 EEST | Business Wire | Press release

Share

Today, the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the results as at 30 June 2020.

Since the start of the year, the Group has recorded a consolidated turnover of €615.2 million, which is an increase of 7.2% compared to the same period in 2019.

All indicators are positive for the period. In the first half of 2020, consolidated EBITDA of €90.2 million compared to the €85.7 million recorded in 2019 and corresponds to 14.7% of turnover.

EBIT, from January to June, was €74.1 million (€67.6 million in 2019), corresponding to 12.1% of turnover.

Pre-tax profit, from January to June 2020, was €75.1 million (€70.2 million in 2019), corresponding to 12.2% of turnover.

As regards the second quarter 2020, the Group's performance was also positive, with consolidated turnover for the period of €298.2 million, up by 2.8% compared to 2019.

EBITDA, from April to June 2020, amounted to €42.6 million, with EBIT of €36.1 million and pre-tax profit of €41.2 million.

As at 30 June 2020, the Group's net financial position was positive for €122.6 million, while at 31 March 2020 was positive for €159.3 million. The financial position at 30 June 2019 was positive for €18.3 million.

"The year 2020 - said Mario Rizzante, Chairman of Reply - will mark history. During February and March, as the Covid19 pandemic spread in the northern hemisphere, the world came to a standstill. Reply had the ability to react in an effective way to this period of unimaginable discontinuity. In less than two days, all of Reply's 8000+ people were able to work remotely. As a result, we were able to continue to honour the commitments we made with our customers, often working on fundamental systems which ensured not only the continuity of their business, but also the survival of entire countries and industries. I am referring, for example, to our involvement in banking and insurance services, to the contribution we have made to telephone operators, to the support we have given to health care services and the logistics chain".

"In these months, despite the difficulties linked to the various lock-downs, - Mario Rizzante added - Reply has continued on its growth path, with positive results in all the geographies where it is operating. This has been possible thanks to our exclusive focus on new technologies and the resilience of our network model which has allowed us to promptly compensate the slowdown in activities linked to sectors particularly affected by the pandemic such as, for example, transport, manufacturing and tourism".

"The current scenario - concluded Mario Rizzante - is constantly changing and it remains very difficult to make predictions about the future in the short and medium term. The recent months have, in any case, definitively changed the perception of technology by all companies. Today even the most traditional and conservative businesses have understood that the digitalization of processes, the cloud and artificial intelligence are essential tools to restart and be competitive in an increasingly connected and digital world".

The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

This press release is a translation, the Italian version will prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Investor Relation
Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594

Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release

Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital

Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 10:30:00 EEST | Press release

Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h

LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 09:16:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include: LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Si

Sofinnova Partners Appoints David Evans as Partner13.7.2026 09:00:00 EEST | Press release

Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye